The recent guidelines for treating RCC include antiangiogenic drugs, immune checkpoint inhibitors, mTOR inhibitors, and other immunotherapies or cytokines; however, they do not currently include agents that specifically regulate the NF-κB or Hippo signaling pathways [45]. The gene discussed is MTOR; the disease is renal cell carcinoma.